Drug Delivery Solutions
NanoOncology
NanoOncology

Nano Oncology Pipeline

EVI1 is a gene highly expressed in breast, prostate, lung, ovarian, skin, and colon cancers. Our product is a small interfering RNA (siRNA) that specifically triggers death of cancer cells. NANO will develop novel nanoparticle drug delivery systems to target our siRNA drugs to specific tumor types. Our first product will be sirRNA-targeting EVI1 to treat ovarian cancer called EVIRNA™.

Nano Oncology Pipeline

Ovarian Cancer Program

A study by Brooks et al. demostrated, by RT-PCR, that EVI1 was highly expressed in 22 of 25 human tumors samples. NANO has demostrated that introducing EVIRNA™ to cultures of ovarian tumor cells decreases the number of viable cells. NANO is advancing this ovarian cancer EVIRNA™ into mouse tumor models.

Read more

Breast Program

EVI1 is highly expressed in certain cancer cell types. A study by Brooks et al. demostrated, by RT-PCR, that EVI1 was highly expressed in more than 50% human breast tumors samples. NANO has demostrated that introducing EVIRNA™ to cultures of breast tumor cells decreases the number of viable cells. NANO is advancing this breast cancer EVIRNA™ into mouse tumor models.

Read more

Lung Cancer Program

The EVI1 gene is amplified in 76% of squamous cell carcinoma, the most abundant type of non-small cell carcinoma. The EVI1 gene is also amplified in lung adenocarcinoma. The expression of EVI1 was significantly higher in 19 of 25 human non-small cell lung cancer samples, as determined by real time quantitative RT-PCR, compared with non tumor tissues. NANO has demostrated that introducing EVIRNA™ to cultures of breast tumor cells decreases the number of viable cells. NANO is advancing this lung cancer EVIRNA™ into mouse tumor models.

Read more

Kang, JU, Koo, SH, Kwon, KC, Park, JW, and Kim, JM. Identification of novel candidate target genes, including EPHB3, MASP1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 2009; 9:237-52.

Yokoi, S, Yasui, K Iizasa, T, Imoto, I, Fijsawa, T, and Inazawa, J. TERC identified as a probabple target within the 3q26 amplicon that is detected frequently in non-small cell lung cancers. Clin Cancers Res. 2003; 9: 4705-4713.

Brooks, DJ, Woodward, S, Thompson, FH, Dos Santos, B, Russell, M Yang, J-M, Guan, X-Y, Trent, J, Alberts, DS, and Taetle, R. Expression of the zinc finger gene EVI1 in ovarian and other cancers.